PURPOSE: Chronic obstructive pulmonary disease (COPD) is characterized by an abnormal inflammatory response of the lung associated with progressive limitation of expiratory airflow. The vasoactive intestinal peptide (VIP) is known to possess anti-inflammatory, vasodilator and bronchodilator potencies, which make it a promising candidate for the treatment of COPD.
METHODS: 34 patients with COPD (stage I-IV) were included in our double-blind randomized trial and received 200 μg of aerosolized VIP applied in 4 inhalations per day for either 6 or 3 months (first 3 months placebo) . Primary endpoints were the changes in exercise capacity as measured by the 6 minute walk test and spiroergometry (SPE), and in quality of life assessed by the St. George's Respiratory Questionnaire (SGRQ) and SF-36 Questionnaire.
RESULTS: We present preliminary data of 25 patients who already finished the trial and could be evaluated. The 6 minute walking distance (6MWD) showed a statistically significant increase from baseline to month 6 (464.7 ± 97.6 m vs. 491.5 ± 110.7 m, p<0.05), whereas the maximum performance in SPE did not change. Quality of life assessment at baseline and month 6 showed a significant improvement in the SGRQ total score (45.2 ± 16.3 vs. 37.8 ±17.8, p<0.05), and a tendency towards improvement in the SF-36 mental component summary (45.0 ± 9.6 vs. 50.0 ± 13.2, p=0.067). No severe side effects were observed.
CONCLUSION: The preliminary data of the VIP/COPD-trial confirm our previous results, demonstrating a positive impact of VIP on exercise capacity and quality of life in patients with COPD.
CLINICAL IMPLICATIONS: Taken together, VIP might be a promising agent for treatment of COPD because of its anti-inflammatory, bronchodilatatory and vasodilatatory effects.
DISCLOSURE: Bernhard Burian, None.